Regnum (Regnum) Inventories, Work In Process : $0.00 Mil (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Regnum Inventories, Work In Process?

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Regnum's work in process for the quarter that ended in Mar. 2023 was $0.00 Mil.

Regnum Inventories, Work In Process Historical Data

The historical data trend for Regnum's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Inventories, Work In Process Chart

Regnum Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Inventories, Work In Process

Get a 7-Day Free Trial

Regnum Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Inventories, Work In Process	Get a 7-Day Free Trial															-	-	-	-	-

Regnum Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

Regnum (Regnum) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Inventories, Work In Process

Comparable Companies

Traded in Other Exchanges

N/A

Address

600 Third Avenue, 19th Floor, New York, NY, USA, 10016

Website

https://www.regnumcorp.com

Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines